Results 61 to 70 of about 119,088 (108)
Figure S3 from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma
, 2019 Effects of ADI-PEG20 on the folate ...Tomasz Matys (15019824), Stephen Ellis (3088218), Raj Jena (15019821), Xiaoxing Feng (2211154), Kate Smith (553279), Kevin O'Neill (8667702), Richard Shaffer (15019806), Jim A. Thomson (15019815), Ramsay S. Khadeir (15019827), Fiona P. Harris (15019818), Bor-Wen Wu (14914755), Amanda Johnston (15019812), Michael Sheaff (419361), Peter W. Szlosarek (14914764), Simon Pacey (5508092), Matthew Williams (15019809), Peter E. Hall (15019803), Rachel Lewis (246649), Piers N. Plowman (15019830), Nelofer Syed (1455205), Dimitris Paraskevopoulos (9361523), Timothy Crook (10659593), Jane Evanson (3463304), Sarah Jefferies (4030895), John S. Bomalaski (14914758) +24 morecore +1 more sourceA Phase II Trial of ADI-PEG20 in Combination with Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma
Background
Arginine deprivation with pegylated arginine deiminase (ADI-PEG 20, pegargiminase) may enhance chemotherapy efficacy in soft tissue sarcomas (STS). We conducted a phase II trial (NCT03449901) evaluating ADI-PEG20 plus gemcitabine/docetaxel in Xiachun Zhang, Kristen Ganjoo, Gary Schwartz, Nam Bui, Caitlyn Brashears, Carina Dehner, Sasha Haarberg, Tyler Ruff, John Bomalaski, Matthew Ingham, Angela Hirbe, Dana Borcherding, Mia Weiss, Jingqin Luo, Amanda Johnston, Brian Van Tine, Toshinao Oyama, Miguel Ruiz Cardozo, Sant Chawla, Peter Oppelt, Ruichen Ye, Vanessa Eulo, Jacqui Toeniskoetter, Alliny Bastos da Silva, Jessy Shui, Jennifer Kuo +25 morecore +1 more sourceSelective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells
, 2017 Arginine depletion strategies, such as pegylated recombinant arginine deiminase (ADI-PEG20), offer a promising anticancer treatment. Many tumor cells have suppressed expression of a key enzyme, argininosuccinate synthetase 1 (ASS1), which converts ...Yeh, Tzyy-Harn;Chen, Yun-Ru;Chen, Szu-Ying;Shen, Wei-Chiang;Ann, David K.;Zaro, Jennica L.;Shen, Li-Jiuan, 沈麗娟 +1 morecore +1 more sourceA Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma. [PDF]
, 2019 PURPOSE: Patients with recurrent high-grade gliomas (HGG) are usually managed with alkylating chemotherapy ± bevacizumab. However, prognosis remains very poor. Preclinically, we showed that HGGs are a target for arginine depletion with pegargiminase (ADI-Matys, T, Crook, Timothy, Hall, Peter E, O'Neill, K, Feng, X, Ellis, S, Bomalaski, JS, Matys, Tomasz, Pacey, Simon, Lewis, R, Jefferies, S, Hall, PE, Johnston, Amanda, Harris, Fiona P, Lewis, Rachel, Williams, Matthew, Paraskevopoulos, D, Szlosarek, PW, Pacey, S, Syed, Nelofer, Ellis, Stephen, Szlosarek, Peter W, Plowman, PN, Khadeir, RS, Wu, Bor-Wen, Feng, Xiaoxing, Shaffer, R, Harris, FP, Wu, B-W, Sheaff, M, Khadeir, Ramsay S, Bomalaski, John S, Syed, N, Plowman, Piers N, Shaffer, Richard, Smith, K, Evanson, J, Evanson, Jane, Jefferies, Sarah, Crook, T, Johnston, A, Thomson, JA, Jena, R, Paraskevopoulos, Dimitris, Williams, M, Smith, Kate, Jena, Raj, Sheaff, Michael, Thomson, Jim A, O'Neill, Kevin +49 morecore +2 more sourcesSelective Intracellular Delivery of Recombinant Arginine
Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome
ADI Resistance in Hypoxic Breast Cancer Cells
, 2016 Arginine
depletion strategies, such as pegylated recombinant arginine
deiminase (ADI-PEG20), offer a promising anticancer treatment. Many
tumor cells have suppressed expression of a key enzyme, argininosuccinate
synthetase 1 (ASS1), which converts ...Tzyy-Harn Yeh (1447432), Li-Jiuan Shen (1447438), Wei-Chiang Shen (223030), Yun-Ru Chen (54058), David K. Ann (665043), Jennica L. Zaro (1447435), Szu-Ying Chen (1447441) +6 morecore +1 more sourceCorrection: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma. [PDF]
Pharmacol Rep, 2023 Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C, Feng S, Hallden G, Chelala C, Bomalaski J, Steele J, Sheaff M, Balkwill F, Szlosarek PW. +15 moreeuropepmc +1 more sourceArginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma A Randomized Clinical Trial [PDF]
, 2017 IMPORTANCE:
Preclinical studies show that arginine deprivation is synthetically lethal in argininosuccinate synthetase 1 (ASS1)-negative cancers, including mesothelioma.Hillman, P, Crook, Timothy, Nolan, L, Gairin Dancey, Taylor, P, Dancey, Gairin, Mitra, Sankhasuvra, Mitra, S, Jeremy P. Steele, Avril, Norbert E, Teresa Szyszko, Johnston, Amanda, Hackshaw, Allan, Marianne Tomsa, Phillips, Melissa M, Ellis, Stephen, Robin M. Rudd, Beck, S, Avril, NE, Luong, Phuong, Wu, B-W, Szlosarek, Peter W., Fennell, Dean, Butcher, Lee, Thomson, Jim, Spicer, James; id_orcid, Michael Lind, Gilligan, D, Spicer, J, Butcher, L, Rudd, Robin M., Rudd, Robin M, Luke Nolan, Peter Schmid, Melissa M. Phillips, Jonathan Shamash, Luong, P, Sankhasuvra Mitra, Crook, T, Bomalaski, John S., Thomson, J, Fennell, D, Dancey, G, Tomsa, M, Taylor, Paul, Phillips, Melissa M., Paul Hillman, Spicer, James, John S. Bomalaski, Jim Thomson, Lemoine, Nicholas, Michael T. Sheaff, Tomsa, Marianne, Norbert E. Avril, Ellis, S, Bomalaski, JS, Lawrence, C, Dean Fennell, Schmid, Peter, Peter W. Szlosarek, Payne, S, Bor-Wen Wu, Allan Hackshaw, Sheaff, MT, Szyszko, Teresa, Szlosarek, PW, Lind, M, Cheryl Lawrence, Nicholas Lemoine, Phuong Luong, Amanda Johnston, Lawrence, Cheryl, Szlosarek, Peter W, Wu, Bor-Wen, Stephen Ellis, Sarah Payne, Steele, JP, Steele, Jeremy P., Avril, Norbert E., Shamash, Jonathan, Shamash, J, Rudd, RM, Steele, Jeremy P, Paul Taylor, Timothy Crook, Bomalaski, John S, Schmid, P, Beck, Stephan, Phillips, MM, Lind, Michael, Stephan Beck, Payne, Sarah, David Gilligan, Gilligan, David, Lemoine, N, Sheaff, Michael T., Lee Butcher, Hackshaw, A, Johnston, A, Szyszko, T, Nolan, Luke, James Spicer, Sheaff, Michael T, Hillman, Paul +103 morecore +1 more sourceArginine Deprivation as a Targeted Therapy for Cancer
, 2008 Certain cancers may be auxotrophic for a particular amino acid and amino acid deprivation is one method to treat these tumors. Arginine deprivation is a novel approach to target tumors which lack argininosuccinate synthetase (ASS) expression.Feun, L, Spector, S, Wu, C.J, Wangpaichitr, M, You, M, Kuo, M.T, Savaraj, N +6 morecore +1 more sourceAbstract 4445: Pegylated arginine deiminase induces mitochondrial apoptosis and synergizes with cisplatin in ASS1-negative malignant pleural mesothelioma
, 2010 We have explored the role of pegylated arginine deiminase (ADI-PEG20), an arginine catabolizing enzyme, in argininosuccinate synthetase 1 (ASS1)-negative malignant pleural mesothelioma (MPM). MPM is a chemorefractory disease, increasing worldwide, with a Claude Chelala, Alex Chacko, Puthen V. Jithesh, Peter W. Szlosarek, Dean A. Fennell, Nicholas R. Lemoine, Barbara Delage +6 morecore +1 more source
